Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (5,961,892)	$ (2,707,535)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	7,117	1,659
Amortization of discounts related to convertible notes payable	675,025	46,150
Amortization of capitalized financing costs	114,128	15,648
Gains on settlement(s) - With former management	(91,710)	(1,038,270)
Gains on settlement(s) - With service providers	$ (75,375)	(393,590)
Gains on settlement(s) - Of project advance		(287,809)
Stock-based compensation expense included in – General and administrative expenses	$ 2,342,895	3,131,500
Stock-based compensation expense included in – Research and development expenses	363,551	99,000
Stock-based compensation expense included in – Foreign currency transaction gain	(13,328)	(43,637)
(Increase) decrease in -
Grant receivable	48,000	(48,000)
Prepaid expenses	46,145	(84,730)
Increase (decrease) in -
Accounts payable and accrued expenses	490,380	452,099
Accrued compensation and related expenses	684,409	(118,084)
Accrued interest payable	108,888	55,397
Unearned grant revenue	(34,333)	34,333
Net cash used in operating activities	(1,296,100)	(885,869)
Cash flows from investing activities:
Purchases of equipment	(2,497)	(18,400)
Net cash used in investing activities	(2,497)	$ (18,400)
Cash flows from financing activities:
Proceeds from sale of common stock units	$ 1,194,710
Proceeds from sale of Series G 1.5% Convertible Preferred Stock		$ 928,500
Proceeds from convertible note and warrant financing	$ 210,000	369,500
Proceeds from issuance of note payable to Chairman	40,000	$ 75,000
Principal paid on other short-term notes payable	(95,152)
Repayment of note payable to Chairman	(40,000)	$ (150,000)
Cash payments made for costs incurred in connection with the sale of common stock units	(104,814)
Cash payments made for deferred costs incurred in connection with convertible note and warrant financing	$ (15,700)	$ (77,410)
Cash payments made for costs incurred in connection with sale of Series G 1.5% Convertible Preferred Stock		(92,921)
Net cash provided by financing activities	$ 1,189,044	1,052,669
Cash and cash equivalents:
Net increase (decrease)	(109,553)	148,400
Balance at beginning of period	162,752	14,352
Balance at end of period	53,199	162,752
Supplemental disclosures of cash flow information:
Interest	$ 6,873	$ 102
Income taxes
Non-cash financing activities:
Amortization of deemed dividend on Series G 1.5% Convertible Preferred Stock		$ 10,049,846
Dividends on Series G 1.5% Convertible Preferred Stock	$ 6,867	10,926
Gross exercise price of Series G 1.5% Convertible Preferred Stock placement agent warrants exercised on a cashless basis	4,778	$ 18,689
Gross exercise price of 10% convertible notes payable placement agent warrants exercised on a cashless basis	35,595
Short-term note payable issued in connection with financing of insurance policy premium	36,125
Stated value of Series G 1.5% Convertible Preferred Stock converted into common stock	621,038	$ 66,689
Fair value of common stock options issued in connection with settlements with former management	26,290	179,910
Fair value of common stock options issued in connection with settlements with service providers	$ 608,064	42,250
Fair value of common stock issued in connection with settlement of project advance		49,000
Fair value of common stock warrants issued to investors in connection with the convertible note and warrant financing	$ 112,557	176,549
Fair value of common stock warrants issued to placement agents in connection with the convertible note and warrant financing	12,726	23,940
Fair value of beneficial conversion feature of convertible notes payable issued to investors in connection with the convertible note and warrant financing	97,443	$ 192,951
Fair value of common stock warrants issued to investors in connection with the extension of the convertible notes	97,188
Fair value of extending common stock warrants issued to investors in connection with the convertible note and warrant financing	180,730
Fair value of beneficial conversion feature of extended convertible notes payable issued to investors in connection with the convertible note and warrant financing	$ 206,689
Fair value of common stock warrants issued to placement agents and selected dealers in connection with the sale of Series G 1.5% Convertible Preferred Stock		$ 664,169
Fair value of common stock warrants issued to placement agents and selected dealers in connection with the sale of common stock units	$ 135,116
Deferred financing costs transferred to additional paid-in capital in connection with sale of Series G 1.5% Convertible Preferred Stock		$ 35,120